SYNCOMF2024-01-012024-03-31 SYNCOMF2024-01-012024-03-31 SYNCOMF2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member SYNCOMF2024-03-31 SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue03Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue03Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults03Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults03Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets03Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SYNCOMF2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524470 SYNCOMF NOTLISTED Syncom Formulations (India) Limited Equity 2023-04-01 2024-03-31 2024-05-17 2024-05-09 INR Lakhs Yearly 16:00:00 18:30:00 2024-05-17 2024-05-17 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Audited Consolidated 745729000.00 30984000.00 776713000.00 378787000.00 50195000.00 -2004000.00 86923000.00 11951000.00 12977000.00 137584000.00 676413000.00 100300000.00 0.00 100300000.00 25828000.00 427000.00 26255000.00 0.00 74045000.00 0.00 0.00 0.00 0.00 74045000.00 16457000.00 90502000.00 0.00 0.00 940000000.00 1 0.10 0.10 0.00 0.00 0.10 0.10 0.00 0.00 0.00 Multi segment 2023-04-01 2024-03-31 Audited Consolidated 2633871000.00 135259000.00 2769130000.00 1315291000.00 271059000.00 -17546000.00 350577000.00 44741000.00 47223000.00 418016000.00 2429361000.00 339769000.00 -239000.00 339530000.00 80845000.00 5543000.00 86388000.00 0.00 253142000.00 0.00 0.00 0.00 0.00 253142000.00 68139000.00 321281000.00 0.00 0.00 940000000.00 1 1941428000.00 0.34 0.34 0.00 0.00 0.34 0.34 0.00 0.00 0.00 OTHER EXPENSES 137584000.00 OTHER EXPENSES 418016000.00 723060000.00 0.00 473344000.00 0.00 1105000.00 0.00 0.00 0.00 24892000.00 0.00 0.00 74357000.00 99249000.00 0.00 2056000.00 1298814000.00 210815000.00 636994000.00 1032984000.00 633834000.00 44821000.00 42778000.00 41200000.00 2432611000.00 0.00 104399000.00 2747825000.00 0.00 0.00 4046639000.00 940000000.00 1941428000.00 2881428000.00 2881428000.00 0.00 0.00 17160000.00 17160000.00 33038000.00 49767000.00 0.00 0.00 99965000.00 724866000.00 241439000.00 21362000.00 987667000.00 41270000.00 36309000.00 0.00 0.00 1065246000.00 0.00 0.00 1165211000.00 4046639000.00 Pharmaceuticals Drugs & Formulations 745452000.00 Renting of Property 9867000.00 Trading of Commodities 21393000.00 Pharmaceuticals Drugs & Formulations 2621806000.00 Renting of Property 40189000.00 Trading of Commodities 107134000.00 776712000.00 2769129000.00 0.00 0.00 776712000.00 2769129000.00 Pharmaceuticals Drugs & Formulations 102255000.00 Renting of Property 8003000.00 Trading of Commodities 1992000.00 Pharmaceuticals Drugs & Formulations 345460000.00 Renting of Property 36962000.00 Trading of Commodities 1849000.00 112250000.00 384271000.00 11951000.00 44741000.00 0.00 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 17/05/2024 2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as Ind AS ) as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. 3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. 4 The Standalone Statement of Assets and Liabilities as at 31st March, 2024 and the Standalone Statement of Cash Flow is provided as an annexure to this statement. 5 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the Auditor’s report provided by the Statutory Auditors have carried out Audit books of Accounts for the Financial year 2023-2024 and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter / Year ended 31st March, 2024 Therefor the company is not required to give statement of Impact of Audit Qualification for Audit report with modified opinion 6 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 7 The figures of the Last Quarter are the balancing figures between the audited figures in respect of full financial year & the published year to date figures upto 3rd quarter of that financial year 8 The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. The company has already utilized the entire amount and no remaining unutilised amount from above. There is no deviation in the project till 31st March, 2024 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately . 9 There is a hike in Other Expenses in Quarter 4 , mainly on account of rise in Ocean Freight and Export Expenses due to Red Sea Shipping Crisis . 10 After closure of The Financial year , The Company has paid fine of Rs 1.84 Lakhs to National Stock Exhange Limited 0.00 100299000.00 339530000.00 Pharmaceuticals Drugs & Formulations 3470649000.00 Renting of Property 473345000.00 Trading of Commodities 102645000.00 4046639000.00 Pharmaceuticals Drugs & Formulations 1132858000.00 Renting of Property 17160000.00 Trading of Commodities 15193000.00 1165211000.00 0.00 1165211000.00 44741000.00 1188000.00 -277913000.00 0.00 -32423000.00 0.00 0.00 -15121000.00 0.00 36970000.00 0.00 -7633000.00 0.00 47049000.00 0.00 10118000.00 0.00 1144000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -126388000.00 0.00 0.00 -318268000.00 21262000.00 0.00 0.00 0.00 80845000.00 0.00 -59583000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 81364000.00 0.00 -47267000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 864293000.00 0.00 830196000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -106949000.00 0.00 0.00 0.00 0.00 44741000.00 0.00 6114000.00 -145576000.00 625037000.00 0.00 625037000.00 8797000.00 633834000.00 0.00 0.00 Items that will be reclassified to profit or loss 16457000.00 Items that will be reclassified to profit or loss 68139000.00 16457000.00 68139000.00 0.00 0.00